title: Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria.
abstract: OBJECTIVE
  The World Health Organization (WHO) reclassified atypical meningiomas in 2000, creating a more clear and broadly accepted definition. In this paper, the authors evaluated the pathological and clinical transition period for atypical meningiomas according to the implementation of the new WHO grading system at their institution.
  
  
  METHODS
  A total of 471 meningiomas occurring in 440 patients between 1994 and 2006 were retrospectively reviewed to determine changes in diagnostic rates, postoperative treatment trends, and early outcomes.
  
  
  RESULTS
  Between 1994 and 2000, the incidence of the atypical meningiomas ranged from 0 to 3/year, or 4.4% of the meningiomas detected during the entire period. After 2002, the annual percentage of atypical meningiomas rose over a 2-year period, leveling off at between 32.7 and 35.5% between 2004 and 2006. The authors also found a recent trend toward increased use of adjuvant radiation therapy for incompletely resected atypical meningiomas. Prior to 2003, 18.7% were treated with this therapy; after 2003, 34.4% of lesions received this treatment. Incompletely resected tumors were treated with some form of radiation 76% of the time. In cases of complete resection, most patients were not given adjuvant therapy but were expectantly managed by close monitoring using serial imaging and by receiving immediate treatment for tumor recurrence. The overall recurrence rate for expectantly managed tumors was 9% over 28.2 months, and 75% of recurrences responded to delayed radiation therapy.
  
  
  CONCLUSIONS
  The authors documented a significant change in the proportion of meningiomas designated as atypical during a transition period from 2002 to 2004, and propose a conservative strategy for the use of radiation therapy in atypical meningiomas.
authors.affiliation: Division of Neurosurgery, University of Alabama at Birmingham, Alabama 35294-3410, USA.
authors.forename: Blake E
authors.initials: BE
authors.lastname: Pearson
authors.forename: James M
authors.initials: JM
authors.lastname: Markert
authors.forename: Winfield S
authors.initials: WS
authors.lastname: Fisher
authors.forename: Barton L
authors.initials: BL
authors.lastname: Guthrie
authors.forename: John B
authors.initials: JB
authors.lastname: Fiveash
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Palmer
authors.forename: Kristen
authors.initials: K
authors.lastname: Riley
mesh_terms: D000465:Algorithms; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D019468:Disease Management; D006801:Humans; D033183:Interdisciplinary Communication; D008577:Meningeal Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D008579:Meningioma / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D016634:Radiosurgery; D018714:Radiotherapy, Adjuvant / Q000706:statistics & numerical data / Q000639:trends*; D012086:Reoperation; D012189:Retrospective Studies; D016879:Salvage Therapy